CJC-1295 and Ipamorelin: The Growth Hormone Stack Explained

CJC-1295 and ipamorelin are two peptides that work synergistically to amplify the body’s natural growth hormone release through two different receptor pathways. Used together, they produce a stronger and more sustained GH pulse than either does alone, while still working through the body’s natural pulsatile release pattern rather than substituting for GH directly. The CJC-1295 ipamorelin stack has become one of the more commonly prescribed peptide protocols for body composition, sleep architecture, and recovery support in adults dealing with the GH-axis dimension of aging. This guide covers each peptide individually, why they are combined, how the stack compares to sermorelin alone, the candidate profile, and what monitoring looks like during treatment.

CJC-1295: The Long-Acting GHRH Analog

CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH), the hypothalamic peptide that signals the pituitary to release growth hormone. The “1295” designation refers to the specific molecular modifications that distinguish it from natural GHRH. CJC-1295 exists in two forms: with DAC (drug affinity complex) and without. CJC-1295 with DAC has a substantially extended half-life of about 8 days due to a lysine modification that allows it to bind to serum albumin. CJC-1295 without DAC has a much shorter half-life of about 30 minutes, similar to natural GHRH and to sermorelin.

The without-DAC form is the more commonly used variant in clinical practice for stack protocols because the shorter half-life preserves the pulsatile release pattern that more closely mimics natural GH physiology. The with-DAC form produces more sustained GHRH receptor activation, which can shift the GH release pattern toward continuous elevation rather than pulses; this is generally considered less physiologically appropriate, though it has its proponents for specific applications.

CJC-1295 acts on the GHRH receptor on pituitary somatotroph cells, the same receptor that natural GHRH uses. The signal triggers GH release from the pituitary’s existing GH stores. The effect is amplified by the half-life advantage over natural GHRH (even the without-DAC form is more stable than the natural peptide), which produces a stronger and slightly more sustained pituitary signal than the body’s own GHRH does in baseline aging.

Ipamorelin: The Selective GHRP

Ipamorelin is a synthetic peptide in the growth-hormone-releasing peptide (GHRP) class. Unlike CJC-1295, which acts on the GHRH receptor, ipamorelin acts on the ghrelin receptor (also called the GH-secretagogue receptor) on pituitary somatotroph cells. This is a different receptor than the GHRH receptor, with different downstream signaling, but the end effect is the same: GH release from the pituitary.

Ipamorelin is distinguished from earlier GHRPs (GHRP-2, GHRP-6, hexarelin) by its selectivity. Earlier GHRPs cause notable side effects in addition to GH release, including increases in cortisol, prolactin, and ACTH, plus pronounced increases in appetite. A PubMed study comparing ipamorelin to other GH secretagogues documented that ipamorelin produces GH release without significantly affecting cortisol, prolactin, or ACTH, and with minimal effect on appetite. This selectivity makes ipamorelin the preferred GHRP for clinical use, particularly in protocols where the cortisol or appetite side effects of earlier GHRPs would be problematic.

The half-life of ipamorelin is short, around 2 hours, which means it works in pulses similar to the body’s natural GH release pattern. The short half-life is part of why ipamorelin is well-tolerated; the pulsatile signal does not produce continuous elevation that downregulates receptors over time.

Why CJC-1295 Ipamorelin Are Combined

The synergy between CJC-1295 and ipamorelin reflects a basic principle of pituitary GH release: the pituitary responds most strongly when both the GHRH receptor and the ghrelin receptor are stimulated simultaneously. Stimulating either alone produces a moderate GH release; stimulating both at once produces a release that is greater than the sum of either signal alone. This is why the stack produces meaningfully stronger effects than either peptide as a standalone protocol.

The two-pathway approach also has a smoothing effect on the GH release pattern. CJC-1295 increases the amplitude of GH pulses (each pulse is larger). Ipamorelin both amplifies pulses and helps maintain pulsatility from the ghrelin-receptor side. Together they restore the GH release pattern toward a more youthful profile rather than producing supraphysiologic peaks that can downregulate the system over time.

For patients seeking the GH-axis effects (body composition, sleep architecture, recovery), the combination stack is generally chosen when sermorelin alone has produced insufficient response, when the patient’s baseline GH-axis status is more significantly suppressed, or when the clinical goal includes more pronounced body composition effects. For patients with milder needs or who prefer the simpler single-peptide protocol, sermorelin remains a reasonable first choice.

CJC-1295 Ipamorelin vs Sermorelin: How to Choose

Sermorelin is the older, more extensively studied, and simpler protocol. It is a single peptide (a GHRH analog with structural similarity to natural GHRH), administered as a nightly subcutaneous injection. The clinical effects are real but modest, developing over 3 to 6 months of consistent use. Sermorelin’s strongest clinical case is in patients with relatively mild GH-axis decline who want a measured, lower-cost approach with the longest track record of clinical use.

The CJC-1295 ipamorelin stack produces stronger GH release through the dual-receptor mechanism. Body composition effects tend to be more pronounced and develop somewhat faster than with sermorelin alone, though still on the 3-to-6-month timeline rather than weeks. The cost is higher than sermorelin because two peptides are involved. The injection schedule is similar (nightly subcutaneous), and the safety profile remains favorable because pulsatile release is preserved.

The clinical decision between the two often comes down to the specific patient picture. Patients with significantly suppressed IGF-1 at baseline, more pronounced body composition concerns, or insufficient response to a sermorelin trial are reasonable candidates for the stack. Patients with more modest concerns or who have not yet trialed any GH-axis protocol often start with sermorelin and escalate to the stack only if response is insufficient.

Who Is a Candidate for the Stack at Tactus Health

The candidate profile for CJC-1295 ipamorelin therapy at Tactus Health is patients pursuing body composition and recovery improvements where lab work confirms the GH-axis is contributing to the picture. The evaluation includes IGF-1 (the standard marker of GH-axis status), thyroid function, fasting insulin, sex hormones, and the broader metabolic and nutritional markers that affect how the patient will respond to GH-axis support. Patients with low IGF-1 are stronger candidates than patients with normal IGF-1, though the symptom picture matters alongside the labs.

The general profile that responds well includes adults over 35 with reduced muscle mass or difficulty maintaining muscle, increased visceral or abdominal fat despite reasonable diet and training, slowed recovery from exercise or injury, sleep architecture concerns (particularly reduced deep sleep), and either documented IGF-1 suppression or a clinical picture consistent with GH-axis decline. Patients pursuing competitive athletic performance enhancement are not the target population; the legal and ethical framework around peptide therapy is for clinical indications rather than competitive enhancement.

Contraindications include active cancer (because GH-axis stimulation theoretically supports cell proliferation including malignant cells), uncontrolled diabetes (because GH counter-regulates insulin and can worsen glucose control), pregnancy or active fertility planning, and patients with documented pituitary tumors or significant pituitary dysfunction. Patients with sleep apnea or fluid retention concerns require careful evaluation before starting.

What to Expect and Monitoring

The protocol is typically nightly subcutaneous injection of both peptides at bedtime, which mimics the natural GH release pattern that occurs during deep sleep. Some protocols use a 5-days-on, 2-days-off pattern to preserve pituitary responsiveness over long-term use; others use continuous nightly dosing with periodic breaks. The specific protocol is matched to the individual based on baseline IGF-1, response to initial dosing, and the patient’s broader picture.

What patients typically notice first is sleep quality improvement, often within 2 to 4 weeks. The deeper sleep produces better recovery and often the first observed energy and clarity changes. Body composition effects develop over 3 to 6 months, with visible changes typically appearing around the 3-month mark for patients also training appropriately. Recovery from exercise and minor injuries typically improves within the first 6 to 8 weeks. Skin quality and other less-tracked benefits develop more gradually over the same timeline.

Monitoring includes IGF-1 at baseline and at 3 months, with the goal of confirming the protocol is producing meaningful elevation without pushing IGF-1 above the upper end of the normal range. Glucose and HbA1c are monitored because GH-axis stimulation can affect glucose regulation, particularly in patients with insulin resistance at baseline. Side effects to watch for include injection site reactions (typically mild and self-limiting), occasional vivid dreams during the first 2 to 4 weeks of use, and rare reports of carpal tunnel-like symptoms or fluid retention at higher doses, which usually resolve with dose adjustment.

Common Patient Questions

How is CJC-1295 ipamorelin different from HGH injections? HGH (recombinant human growth hormone) is the hormone itself, delivered directly. The CJC-1295 ipamorelin stack signals the pituitary to release more of the body’s own GH through pulsatile release. The pulsatile pattern is more physiologically appropriate, the safety profile is better, and the feedback regulation is preserved. HGH produces stronger and faster effects but with greater risk of side effects (carpal tunnel, fluid retention, glucose dysregulation) and a less favorable long-term profile.

Can I use one without the other? Yes. CJC-1295 alone is a reasonable protocol for patients who want the GHRH-receptor stimulation without the GHRP component. Ipamorelin alone is occasionally used, though the GHRH signal from CJC-1295 is generally what provides the larger amplitude. The stack produces more response than either alone, which is why the combination is the standard approach.

What about CJC-1295 with DAC instead of without DAC? The with-DAC form has a much longer half-life (about 8 days) and produces continuous rather than pulsatile receptor activation. Most clinicians prefer the without-DAC form for the more physiologically appropriate pulsatile pattern, though with-DAC has its uses in specific protocols. The default at Tactus Health is the without-DAC form for stack protocols.

How long do I stay on the stack? Treatment is typically reassessed at 3 to 6 month intervals. Some patients use the stack as an ongoing protocol with periodic breaks to preserve pituitary responsiveness. Others use it for a defined goal (body composition transformation alongside training, recovery from a significant injury) and taper off once the goal is reached. The duration is individualized based on the goal and the response.

Is the stack legal? The peptides are used clinically under the compounding framework. The regulatory landscape has been dynamic, and patients should understand both the clinical evidence position and the current regulatory environment. Working with a clinical practice that operates within current guidance is the practical answer.

The Bottom Line

The CJC-1295 ipamorelin stack uses two-pathway pituitary stimulation to produce stronger GH release than either peptide alone, while preserving the pulsatile release pattern that distinguishes peptide therapy from direct HGH replacement. The stack is appropriate for adults pursuing body composition, sleep, and recovery improvements where the GH-axis is contributing to the picture, when paired with appropriate training, nutrition, and lab monitoring. The case for the stack over sermorelin alone is stronger in patients with more significant GH-axis suppression or more pronounced clinical goals; sermorelin remains a reasonable first-line option for milder presentations. The realistic timeline for full effects is 3 to 6 months, and the protocol works best as part of a broader plan rather than as a standalone intervention. The evaluation determines which protocol matches the specific picture.

Medically Reviewed By

Dr. Ashar N., DNP, APRN, FNP-C, PMHNP-BC

Co-Founder & Medical Director at Tactus Health. Dual board-certified, with clinical focus on peptide therapy, hormone optimization, and medical weight loss. Sugar Hill, GA and telehealth for Georgia patients.